Tracey Lodie - Gamida Cell Chief Scientific Officer
| GMDA Stock | USD 0.03 0.01 17.22% |
Executive
Dr. Tracey Lodie is Chief Scientific Officer of the company. Dr. Lodie is an immunologist with over 16 years of drug discovery experience in the areas of autoimmunity, transplant biology and immunooncology. Prior to joining Gamida Cell, Dr. Lodie served as senior vice president, translational immunology at BlueRock Therapeutics, where she helped to advance their universal pluripotent stem cell platform into central nervous system, cardiovascular, and autoimmune therapeutic areas. She also served as vice president of immunology at Syros Pharmaceuticals, where she developed new autoimmunity and immunooncology research programs. Prior to Syros Pharmaceuticals, Dr. Lodie spent over 14 years at SanofiGenzyme, where she held roles of increasing responsibility. At SanofiGenzyme, Dr. Lodie was instrumental in advancing several development programs through regulatory approval in the area of transplant and autoimmunity. Dr. Lodie has experience as an academic instructor and has served in various industry related and nonprofit leadership roles, including scientific advisory boards since 2019.
| Age | 54 |
| Tenure | 5 years |
| Professional Marks | Ph.D |
| Address | 5 Nahum Heftsadie Street, Jerusalem, Israel, 91340 |
| Phone | 972 2 659 5666 |
| Web | https://www.gamida-cell.com |
Gamida Cell Management Efficiency
The company has return on total asset (ROA) of (0.4147) % which means that it has lost $0.4147 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (11.0379) %, meaning that it created substantial loss on money invested by shareholders. Gamida Cell's management efficiency ratios could be used to measure how well Gamida Cell manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Equity is expected to grow to 22.43, whereas Return On Tangible Assets are forecasted to decline to (0.65). At present, Gamida Cell's Other Current Assets are projected to increase significantly based on the last few years of reporting. The current year's Total Current Assets is expected to grow to about 73 M, whereas Total Assets are forecasted to decline to about 100.3 M.The company currently holds 82.94 M in liabilities. Gamida Cell has a current ratio of 2.52, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Gamida Cell until it has trouble settling it off, either with new capital or with free cash flow. So, Gamida Cell's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Gamida Cell sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Gamida to invest in growth at high rates of return. When we think about Gamida Cell's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Mark MBA | X4 Pharmaceuticals | 60 | |
| RPh Young | Seres Therapeutics | 57 | |
| Michael Szumera | Hookipa Pharma | N/A | |
| Marcy Nanus | Protalix Biotherapeutics | N/A | |
| David Mantus | X4 Pharmaceuticals | 53 | |
| Kenneth MD | Lexicon Pharmaceuticals | 67 | |
| James MBA | Iovance Biotherapeutics | N/A | |
| Pharm MPH | X4 Pharmaceuticals | N/A | |
| Prof MD | Day One Biopharmaceuticals | 55 | |
| Robert Arbeit | X4 Pharmaceuticals | 76 | |
| Philippa Keith | Terns Pharmaceuticals | N/A | |
| Elly MD | Day One Biopharmaceuticals | N/A | |
| Carrie Siragusa | Lexicon Pharmaceuticals | N/A | |
| Caroline Holda | Seres Therapeutics | N/A | |
| Tracy Winton | Iovance Biotherapeutics | N/A | |
| Sara Pellegrino | Iovance Biotherapeutics | N/A | |
| Desiree Gendron | Lexicon Pharmaceuticals | N/A | |
| MBA MD | X4 Pharmaceuticals | 62 | |
| Lisa DeFrancesco | Lexicon Pharmaceuticals | 44 | |
| Dixon Terry | Lexicon Pharmaceuticals | N/A | |
| Sarah McCabe | Iovance Biotherapeutics | N/A | |
Management Performance
| Return On Equity | -11.04 | ||||
| Return On Asset | -0.41 |
Gamida Cell Leadership Team
Elected by the shareholders, the Gamida Cell's board of directors comprises two types of representatives: Gamida Cell inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Gamida. The board's role is to monitor Gamida Cell's management team and ensure that shareholders' interests are well served. Gamida Cell's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Gamida Cell's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Roger Kornberg, Director | ||
| Tracey Lodie, Chief Scientific Officer | ||
| Boaz Lifschitz, Independent Director | ||
| Tzvi Palash, COO | ||
| Kenneth Moch, Independent Director | ||
| Michael Perry, Director | ||
| Ofer Gonen, Director | ||
| Julian Adams, CEO, Director | ||
| Joshua Patterson, General Officer | ||
| Tony Peled, Chief Scientific Officer, Vice President - Research & Development | ||
| Naftali CPA, Senior Operations | ||
| RPh MBA, Chief Officer | ||
| Mary MBA, Principal CFO | ||
| Penny Bushell, Chief Officer | ||
| Joshua Hamermesh, Chief Business Officer | ||
| Paul Nee, VP Marketing | ||
| Vladimir Melnikov, Senior Manufacturing | ||
| Linda Stamler, Vice Management | ||
| Ronit Simantov, Chief Medical Officer | ||
| Heather DiVecchia, Chief Staff | ||
| Shai Lankry, CFO | ||
| Thomas Klima, Chief Commercial Officer | ||
| Robert Blum, Independent Non-Executive Chairman of the Board, | ||
| Ronit MD, Chief Officer | ||
| Abigail Jenkins, CEO President | ||
| Nurit Benjamini, Independent Director |
Gamida Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Gamida Cell a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -11.04 | ||||
| Return On Asset | -0.41 | ||||
| Operating Margin | (26.80) % | ||||
| Current Valuation | 70.28 M | ||||
| Shares Outstanding | 132.64 M | ||||
| Shares Owned By Insiders | 11.57 % | ||||
| Shares Owned By Institutions | 26.48 % | ||||
| Number Of Shares Shorted | 10.96 M | ||||
| Price To Earning | (3.97) X | ||||
| Price To Book | 117.40 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in unemployment. Note that the Gamida Cell information on this page should be used as a complementary analysis to other Gamida Cell's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.
Complementary Tools for Gamida Stock analysis
When running Gamida Cell's price analysis, check to measure Gamida Cell's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Gamida Cell is operating at the current time. Most of Gamida Cell's value examination focuses on studying past and present price action to predict the probability of Gamida Cell's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Gamida Cell's price. Additionally, you may evaluate how the addition of Gamida Cell to your portfolios can decrease your overall portfolio volatility.
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges |
Is Gamida Cell's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Gamida Cell. If investors know Gamida will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Gamida Cell listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.82) | Revenue Per Share 0.007 | Return On Assets (0.41) | Return On Equity (11.04) |
The market value of Gamida Cell is measured differently than its book value, which is the value of Gamida that is recorded on the company's balance sheet. Investors also form their own opinion of Gamida Cell's value that differs from its market value or its book value, called intrinsic value, which is Gamida Cell's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Gamida Cell's market value can be influenced by many factors that don't directly affect Gamida Cell's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Gamida Cell's value and its price as these two are different measures arrived at by different means. Investors typically determine if Gamida Cell is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Gamida Cell's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.